Systemic Treatment and Innovative Diagnostics of Advanced Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (20 August 2022) | Viewed by 5915
Special Issue Editors
Interests: prostate cancer; systemic therapy; local therapy; health-related quality of life
Special Issue Information
Dear Colleagues,
The therapeutic landscape of advanced prostate cancer is rapidly evolving and conventional androgen deprivation monotherapy is increasingly being replaced by a plethora of sophisticated combination therapies, including next-generation anti-androgens such as enzalutamide, apalutamide, and darolutamide, as well as abiraterone acetate and docetaxel. However, correct risk stratification and patient selection are still being debated, and evidence regarding clinical, diagnostic, and molecular prognostic and predictive biomarkers is still subpar. In addition, the implementation of PSMA-based imaging as well as LuPSMA and AcPSMA radioligand therapy is ongoing and evidence regarding its clinical use in advanced prostate cancer is steadily growing. Again, patient stratification and the implementation of novel imaging findings in the existing literature are still subject to debate. Finally, with the approval of olaparib and the ongoing clinical evaluation of several other PARP inhibitors, molecular analyses such as next-generation sequencing have come to be essential tools in the modern therapy of patients with metastatic castration-resistant prostate cancer, and further research is warranted. In this Special Issue, we aim to address relevant and ongoing debates regarding the systemic treatment of this disease as well as the current diagnostic strategies used for advanced prostate cancer.
Prof. Dr. Alexander Kretschmer
Dr. Takayuki Sumiyoshi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- metastatic
- androgen deprivation therapy
- metastasis-directed therapy
- abiraterone
- apalutamide
- enzalutamide
- docetaxel
- LuPSMA radioligand therapy
- liquid biopsy
